- Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugsCNBC
- How big pharma is king of the hill in M&AYahoo Finance
- The Twists and Turns in Biopharma Dealmaking: 2024 TrendsPharmaceutical Executive
- Cooley’s 2023 Life Sciences M&A Year in Review: Potent Mix of Creativity and Resilience Spurs Activity Heading Into 2024JD Supra
- Top 10 blockbuster drugs that will become off-patent in 2024MSN